Latest Breaking News On - Head of corporate patient affairs - Page 1 : comparemela.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases .

United statesHead of corporate patient affairsCompensation committee of the board directorsPharmaceuticals incCompany contactPharmaceuticals nasdaqEquity incentive planNasdaq listing rule

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPharmaceuticals to host virtual investor event onHead of corporate patient affairsCompany contactPharmaceuticals nasdaqExchange commissionHost virtual investor eventReview new mavorixafor clinical dataOngoing phaseChronic neutropeniaPrivate securities litigation reform act

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAdam mostafaExchange commissionHercules capital incHead of corporate patient affairsPharmaceuticals nasdaqDrug administrationCompany contactCapital infusionPriority review voucherExisting loanRare pediatric disease priority review voucherHercules capitalChief financial officerRare pediatric diseasePrivate securities litigation reform act

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPaula raganHead of corporate patient affairsEuropean medicines agencyExchange commissionAmerican society of hematologyClinical immunology societyDrug administrationDevelopment rd expensesPharmaceuticals reports firstPharmaceuticals nasdaqCompany contactReports first quarterProvides corporateChief executive officerRare pediatric disease priority review voucher

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPharmaceuticals incHead of corporate patient affairsPharmaceuticals nasdaqCompensation committee of the board directorsCompany contactEquity incentive planNasdaq listing rule